Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q2 2025 Earnings Presentation
15 slides from Anika Therapeutics's earnings presentation, Jul 30, 2025
Slide 1: Q2 2025 Earnings Call
Q2 2025 EARNINGS CALL JULY 30, 2025 Anika. Restore Active Living.
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Company Highlights
COMPANY HIGHLIGHTS STRATEGIC FOCUS DRIVING COMMERCIAL GROWTH AND PIPELINE ADVANCEMENT Commercial Update Pipeline Progress Hyalofast Update • Integrity Implant System • Integrity – received 510(k) approval • Hyalofast FastTRACK study did not exceeding launch expectations and for platform expansion fo
Slide 4: Q2 2025 Financial Highlights
Q2 2025 FINANCIAL HIGHLIGHTS $M, except per share data CONTINUING OPERATIONS 2Q25 Continuing Operations Highlights Q2 Financial Results 2025 VPY • Revenue decreased by 8% to $28.2M driven by 13% Revenue $28.2 (8%) decrease in OEM Revenue due to lower pricing both in transfer units and royalties on M
Slide 5: 2025 Guidance: Updated Long Term Revenue
2025 GUIDANCE: UPDATED LONG TERM REVENUE $M 2021 2022 2023 2024 2025 Est 1 2026 Est 1 2027 Est 1 Commercial Revenue • International OA Pain +17% 3-Year CAGR • Global Regenerative Solutions • US Hyalofast (2027) $47-49.5 +10-20% +10-20% $32 $36 $42 +12-18% $26 OEM Revenue • US OA Pain though J&J • No
Slide 6: Strategies to Deliver Shareholder Value
3 STRATEGIES TO DELIVER SHAREHOLDER VALUE Near-Term: Deliver market leading OA Pain Management products and achieve full potential of Integrity (2025) Implant System in high-growth $220M tendon augmentation TAM Mid-Term: Obtain FDA approval and successfully launch Hyalofast in Anika’s Commercial Cha
Slide 7: Anika
@ Anika
Slide 8: Non-GAAP Reconciliation and Supplemental Data
NON-GAAP RECONCILIATION AND SUPPLEMENTAL DATA 8
Slide 9: Statement of Operations
STATEMENT OF OPERATIONS Anika Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations (in thousands, except per share data) (unaudited) For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Revenue $ 28,219 $ 30,724 $ 54,387 $ 59,746 Cost of Reve
Slide 10: Balance Sheet
BALANCE SHEET Anika Therapeutics, Inc. and Subsidiaries Consolidated Balance Sheets (in thousands, except per share data) (unaudited) June 30, December 31, ASSETS 2025 2024 Current assets: Cash and cash equivalents $ 53,167 $ 55,629 Accounts receivable, net 23,955 23,594 Inventories, net 16,922 23,8
Slide 11: Reconciliation Tables – GAAP Net Loss to Adjusted EBITDA
RECONCILIATION TABLES – GAAP NET LOSS TO ADJUSTED EBITDA Anika Therapeutics, Inc. and Subsidiaries Reconciliation of GAAP Net Loss from Continued Operations to Adjusted EBITDA (in thousands) (unaudited) For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Net los
Slide 12: Reconciliation Tables – GAAP Net Income to Adjusted Net Income
RECONCILIATION TABLES – GAAP NET INCOME TO ADJUSTED NET INCOME Anika Therapeutics, Inc. and Subsidiaries Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations (in thousands) (unaudited) For the Three Months Ended June 30, For the Six Months En
Slide 13: Reconciliation Tables – GAAP EPS to Adjusted EPS
RECONCILIATION TABLES – GAAP EPS TO ADJUSTED EPS 13
Slide 14: Revenue by Channel
REVENUE BY CHANNEL OEM Channel Commercial Channel Revenue QAnNika Revenue by Product Family {in thousands, except percentages) (unaudited) For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 $ change % change 2025 2024 $ change % change $ 16,340 $ 18,887 $ (2,547) -13% $
Slide 15: Anika
@ Anika